<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099786</url>
  </required_header>
  <id_info>
    <org_study_id>C0239-R</org_study_id>
    <secondary_id>3114</secondary_id>
    <nct_id>NCT02099786</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparison of Ototoxicity Monitoring Programs</brief_title>
  <acronym>COMP-VA</acronym>
  <official_title>Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves research. Some chemotherapeutic drugs that can permanently reduce hearing
      are termed &quot;ototoxic&quot;. One such drug is the chemotherapy called cisplatin. Currently, if a
      patient is receiving cisplatin, hearing is tested in the Audiology Clinic using lengthy
      protocols and may be retested only when it is requested by their oncologist and when the
      Veteran can arrange an appointment. Researchers think that hearing testing prior to every
      treatment of cisplatin may reduce the number of Veterans who get disabling hearing loss from
      treatment. The purpose of this study is to compare the current method of monitoring hearing
      (audiology clinic protocols termed &quot;usual care&quot;) with a new portable hearing monitoring
      program (a comprehensive program of ototoxicity monitoring termed &quot;COMP-VA&quot;) that tests
      hearing using a portable hearing testing audiometer and a variety of efficient tools and
      techniques so that testing can occur prior to each cisplatin treatment at any quiet location
      in the hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research objectives are to compare the effectiveness of ototoxicity monitoring implemented
      using Comp-VA or usual care with regard to (1) improving Veterans' hearing and quality of
      life outcomes, (2) assisting oncologists in pre-treatment counseling and therapeutic planning
      and (3) increasing use of post-treatment rehabilitative services.

      The investigators plan to recruit a total of 320 Veterans undergoing cisplatin
      chemotherapeutic treatment over 4 years and 120 control subjects.

      Program Evaluation: Hearing testing prior to treatment will be done in order to establish
      eligibility, enroll and randomize each subject into one of two study arms. At 5 weeks and at
      one year post-randomization hearing will be re-tested in order to obtain an estimate of
      longitudinal trends in hearing and quality of life assessment. Use of audiological services
      following treatment from the randomized subjects will be tracked. Finally, data will also be
      collected at each treatment interval to track use of counseling tools and oncology personnel
      treatment decisions.

      Serial measurements from subjects receiving cisplatin prior to treatment who are randomized
      to:

      Comp-VA group will get a screening hearing test prior to treatment, at each treatment
      interval and at one-month post-treatment. Auditory testing will be done on or near the Chemo
      Unit and will include otoscopy, immittance testing, and a hearing testing done by the Veteran
      using a self-testing procedure, and may be tested using distortion product otoacoustic
      emissions (DPOAEs), if they cannot take a reliable hearing test.

      Usual care group will receive a full audiometric evaluation (otoscopy, immittance testing,
      air conduction and bone conduction hearing testing, speech audiometry, and distortion product
      otoacoustic emissions, DPOAEs) scheduled in the audiology clinic sound booth according to
      Audiology Service ototoxicity monitoring protocols. Testing will be arranged according to
      availability of appointments and patient convenience.

      Additionally data will also be collected from control subjects who are similar in age and are
      tested at intervals similar to the chemotherapy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">May 5, 2018</completion_date>
  <primary_completion_date type="Actual">May 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Ototoxic Hearing Shift</measure>
    <time_frame>35 days post randomization</time_frame>
    <description>Veterans randomized to the COMP-VA arm will have improved hearing outcomes (a) fewer ASHA-significant threshold shifts, (b) fewer CTCAE grade 1 or greater hearing shifts at Program Evaluation 3 as compared with Veterans randomized to the Usual Care arm.
ASHA Shift is defined as:
20 dB shift at a single frequency 10 dB shift at two adjacent frequencies loss of response at three adjacent frequencies
CTCAE Grade 1 or greater ototoxicity = hearing shift of 15-25 dB averaged at 2 contiguous test frequencies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Accessed the Audiology Clinic for Aural Rehabilitation</measure>
    <time_frame>through study completion, an average of 1 year post randomization</time_frame>
    <description>Veterans randomized to Comp-VA will access and use audiology rehabilitation at higher rates than usual care up to 1 year post-treatment. This includes: New hearing aid issued; Hearing aid adjustments made; Technology updated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Mortality</measure>
    <time_frame>1 year post randomization</time_frame>
    <description>Mortality among participants defined as differences in rates of death within one year of randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing-related Quality of Life Measure</measure>
    <time_frame>1 year post randomization</time_frame>
    <description>Differences in the Hearing Handicap Inventory for Adults (HHIA) questionnaire score [or Hearing Handicap Inventory for the Elderly (HHIE) score as appropriate] depending on the age of the subject.
Minimum possible value = 0 Maximum possible value = 100 A higher score indicates poorer performance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Cisplatin Ototoxicity</condition>
  <condition>Hearing Loss</condition>
  <arm_group>
    <arm_group_label>COMP-VA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hearing testing at each treatment and at 1 month following treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hearing testing done according to Audiology Clinic protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COMP-VA</intervention_name>
    <description>Hearing testing at each treatment interval by the comp-va audiologist</description>
    <arm_group_label>COMP-VA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Hearing testing done in the audiology clinic after oncology referral or patient self referral</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Veterans entering cisplatin chemotherapy will be informed of the project and invited to
        participate unless the Veteran was excluded by CPRS review or medical advice.

        Exclusion Criteria:

          -  Experimental subjects must be prescribed cisplatin for treatment of cancer to be
             enrolled in the treatment arms of this study.

        Criteria for excluding subjects (chemotherapy and controls subjects) from this study will
        be:

          -  cognitively or physically unable to participate (patient or nurse report patient is
             incapable of participating), CPRS indication that subject exhibits aggressive
             behavior, subject has documented dementia, Alzheimer's disease, or severe psychosocial
             disorder, CPRS notes indicate individual is not legally capable of providing informed
             consent (subject has a legal guardian)

          -  unable to provide reliable behavioral hearing test responses (for either program
             evaluation hearing test or baseline, pre -treatment hearing test) as indicated by
             intra-session behavioral threshold reliability criterion of &gt; +5 dB)

          -  exhibits Meniere's disease or retrocochlear disorder based on hearing test results,
             patient report or notes in CPRS

          -  exhibits active or recent history of middle ear disorder based on otoscopy,
             tympanometry, patient report, or notes in CPRS

          -  unwilling to participate

          -  hearing thresholds &gt; 70 dB SPL at 4 kHz and below (based on DPOAE 'no response' data
             from a similar protocol described in Bibliography Reference 32, Table 3). The last
             exclusion was adopted in an effort to increase the potential that DPOAEs will be
             measurable in a large number of subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn L Konrad-Martin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brungart D, Schurman J, Konrad-Martin D, Watts K, Buckey J, Clavier O, Jacobs PG, Gordon S, Dille MF. Using tablet-based technology to deliver time-efficient ototoxicity monitoring. Int J Audiol. 2018 Sep;57(sup4):S25-S33. doi: 10.1080/14992027.2017.1370138. Epub 2017 Sep 12. Review.</citation>
    <PMID>28893111</PMID>
  </reference>
  <reference>
    <citation>Dille MF, McMillan GP, Helt WJ, Konrad-Martin D, Jacobs P. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment. J Am Acad Audiol. 2015 Oct;26(9):750-60. doi: 10.3766/jaaa.15028.</citation>
    <PMID>26415968</PMID>
  </reference>
  <reference>
    <citation>Reavis KM, McMillan GP, Dille MF, Konrad-Martin D. Meta-Analysis of Distortion Product Otoacoustic Emission Retest Variability for Serial Monitoring of Cochlear Function in Adults. Ear Hear. 2015 Sep-Oct;36(5):e251-60. doi: 10.1097/AUD.0000000000000176.</citation>
    <PMID>25985018</PMID>
  </reference>
  <reference>
    <citation>Konrad-Martin D, Knight K, McMillan GP, Dreisbach LE, Nelson E, Dille M. Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring. Ear Hear. 2020 Mar/Apr;41(2):239-253. doi: 10.1097/AUD.0000000000000536.</citation>
    <PMID>29280917</PMID>
  </reference>
  <reference>
    <citation>Konrad-Martin D, Poling GL, Garinis AC, Ortiz CE, Hopper J, O'Connell Bennett K, Dille MF. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. Int J Audiol. 2018 Sep;57(sup4):S3-S18. doi: 10.1080/14992027.2017.1398421. Epub 2017 Nov 20. Review. Erratum in: Int J Audiol. 2018 Sep;57(sup4):S108.</citation>
    <PMID>29157038</PMID>
  </reference>
  <reference>
    <citation>Garinis AC, Cornell A, Allada G, Fennelly KP, Maggiore RJ, Konrad-Martin D. Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology. Int J Audiol. 2018 Sep;57(sup4):S19-S24. doi: 10.1080/14992027.2017.1381769. Epub 2017 Oct 5.</citation>
    <PMID>28978238</PMID>
  </reference>
  <reference>
    <citation>Konrad-Martin D, Poling GL, Dreisbach LE, Reavis KM, McMillan GP, Lapsley Miller JA, Marshall L. Serial Monitoring of Otoacoustic Emissions in Clinical Trials. Otol Neurotol. 2016 Sep;37(8):e286-94. doi: 10.1097/MAO.0000000000001134. Review.</citation>
    <PMID>27518137</PMID>
  </reference>
  <reference>
    <citation>Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):81-100. doi: 10.1682/JRRD.2013.04.0092.</citation>
    <PMID>24805896</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <results_first_submitted>May 14, 2019</results_first_submitted>
  <results_first_submitted_qc>September 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2019</results_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hearing</keyword>
  <keyword>cisplatin</keyword>
  <keyword>Ototoxicity</keyword>
  <keyword>Veterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02099786/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02099786/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty-seven Veterans receiving cisplatin for the treatment of cancer were randomized to one of the two treatment arms of the clinical trial. Thirty-six healthy participants were studied to assess normal variability in auditory function measures over time; they were not part of the clinical trial portion of this research project.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>COMP-VA</title>
          <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Program Eval 1</title>
              <participants_list>
                <participants group_id="P1" count="24">Baseline (prior to randomization and first cisplatin dose)</participants>
                <participants group_id="P2" count="23">Baseline (prior to randomization and first cisplatin dose)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Program Eval 2</title>
              <participants_list>
                <participants group_id="P1" count="23">One month post randomization</participants>
                <participants group_id="P2" count="19">One month post randomization</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Program Eval 3</title>
              <participants_list>
                <participants group_id="P1" count="21">One year post randomization</participants>
                <participants group_id="P2" count="15">One year post randomization</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>COMP-VA</title>
          <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="6.4"/>
                    <measurement group_id="B2" value="64.7" spread="9.1"/>
                    <measurement group_id="B3" value="64.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>3, 4, and 6 kHz pure tone average (PTA)</title>
          <units>dB HL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="21.5"/>
                    <measurement group_id="B2" value="55.4" spread="19.8"/>
                    <measurement group_id="B3" value="51.6" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Ototoxic Hearing Shift</title>
        <description>Veterans randomized to the COMP-VA arm will have improved hearing outcomes (a) fewer ASHA-significant threshold shifts, (b) fewer CTCAE grade 1 or greater hearing shifts at Program Evaluation 3 as compared with Veterans randomized to the Usual Care arm.
ASHA Shift is defined as:
20 dB shift at a single frequency 10 dB shift at two adjacent frequencies loss of response at three adjacent frequencies
CTCAE Grade 1 or greater ototoxicity = hearing shift of 15-25 dB averaged at 2 contiguous test frequencies</description>
        <time_frame>35 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COMP-VA</title>
            <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Ototoxic Hearing Shift</title>
          <description>Veterans randomized to the COMP-VA arm will have improved hearing outcomes (a) fewer ASHA-significant threshold shifts, (b) fewer CTCAE grade 1 or greater hearing shifts at Program Evaluation 3 as compared with Veterans randomized to the Usual Care arm.
ASHA Shift is defined as:
20 dB shift at a single frequency 10 dB shift at two adjacent frequencies loss of response at three adjacent frequencies
CTCAE Grade 1 or greater ototoxicity = hearing shift of 15-25 dB averaged at 2 contiguous test frequencies</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in the number of participants with ASHA-significant threshold shifts between treatment arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.27</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.55</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in the number of participants with CTCAE grade 1 or greater hearing loss between treatment arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.67</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.3</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Accessed the Audiology Clinic for Aural Rehabilitation</title>
        <description>Veterans randomized to Comp-VA will access and use audiology rehabilitation at higher rates than usual care up to 1 year post-treatment. This includes: New hearing aid issued; Hearing aid adjustments made; Technology updated.</description>
        <time_frame>through study completion, an average of 1 year post randomization</time_frame>
        <population>All participants who received at least one dose of cisplatin and had at least two Program Evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>COMP-VA</title>
            <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Accessed the Audiology Clinic for Aural Rehabilitation</title>
          <description>Veterans randomized to Comp-VA will access and use audiology rehabilitation at higher rates than usual care up to 1 year post-treatment. This includes: New hearing aid issued; Hearing aid adjustments made; Technology updated.</description>
          <population>All participants who received at least one dose of cisplatin and had at least two Program Evaluations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference in audiology clinic use between treatment arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.88</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.29</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Mortality</title>
        <description>Mortality among participants defined as differences in rates of death within one year of randomization.</description>
        <time_frame>1 year post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COMP-VA</title>
            <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mortality</title>
          <description>Mortality among participants defined as differences in rates of death within one year of randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>We require a non-inferiority margin of no more than 1.1 mortality odds among COMP-VA patients relative to Usual Care patients. This means that the upper 95% confidence bound for the fitted odds ratio must be less than 1.1 to reject the null hypothesis that COMP-VA induces extra mortality risk.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hearing-related Quality of Life Measure</title>
        <description>Differences in the Hearing Handicap Inventory for Adults (HHIA) questionnaire score [or Hearing Handicap Inventory for the Elderly (HHIE) score as appropriate] depending on the age of the subject.
Minimum possible value = 0 Maximum possible value = 100 A higher score indicates poorer performance</description>
        <time_frame>1 year post randomization</time_frame>
        <population>Missing data on some participants due to loss of follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>COMP-VA</title>
            <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral or patient self referral</description>
          </group>
        </group_list>
        <measure>
          <title>Hearing-related Quality of Life Measure</title>
          <description>Differences in the Hearing Handicap Inventory for Adults (HHIA) questionnaire score [or Hearing Handicap Inventory for the Elderly (HHIE) score as appropriate] depending on the age of the subject.
Minimum possible value = 0 Maximum possible value = 100 A higher score indicates poorer performance</description>
          <population>Missing data on some participants due to loss of follow up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="18.6"/>
                    <measurement group_id="O2" value="23.2" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.72</p_value>
            <p_value_desc>The a priori threshold for statistical significance is .05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>COMP-VA</title>
          <description>Hearing testing at each treatment and at 1 month following treatment.
COMP-VA: Hearing testing at each treatment interval by the comp-va audiologist</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Hearing testing done according to Audiology Clinic protocol
Standard of care: Hearing testing done in the audiology clinic after oncology referral</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dawn Konrad-Martin</name_or_title>
      <organization>VA RR&amp;D National Center for Rehabilitative Auditory Research</organization>
      <phone>503-220-8262 ext 52962</phone>
      <email>dawn.martin@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

